A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis
Nephrology Dialysis Transplantation · 13.02.2023 · 38 (2) · 447-454
DOI: 10.1093/ndt/gfac039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 12.02.2022. Verfasst von Harold J Manley und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dialysis Clinic Inc, Nashville, TN, USA. Hauptthemen laut MEDLINE: Hepatitis B Vaccines, Hepatitis B. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Vaccination against hepatitis B virus (HBV) is recommended for dialysis patients. Two reports comparing seroprotection (SP) rates following HepB and HepB-CpG in vaccine-naïve patients with chronic kidney disease enrolled few dialysis patients (n = 122 combined). SP rates in a subset of dialysis patients were not reported or not powered to detect statistically significant differences. SP rates in those requiring additional vaccine series or booster doses are not known.
Methods
A retrospective cohort analysis including dialysis patients completing HepB or HepB-CpG vaccination between January 2019 and December 2020. Vaccine-naïve patients received a series of HepB or HepB-CpG (Series 1). A repeat series was given to nonresponders (Series 2). A booster regimen consists of one dose of either vaccine. Primary outcome was achieving SP (anti-HBs >10 mIU/mL) at least 60 days after the last HBV vaccine dose for Series 1 and Series 2, and achieving SP at least 3 weeks post-booster.
Results
For Series 1 (n = 3509), SP after HepB vaccination was significantly higher (62.9% versus 50.1% for HepB-CpG; P < 0.0001). Series 2 (n = 1040) and booster (n = 2028) SP rates were similar between vaccines. Patients that received up to four HepB-CpG doses had higher SP rates compared with four doses of HepB (82.0% versus 62.9%, respectively; P < 0.0001).
Conclusions
SP rates in hepatitis B vaccine-naïve dialysis patients administered a recommended four doses of HepB were higher than those recommended two doses of HepB-CpG. SP rates were higher and achieved sooner if HepB-CpG was utilized initially and, if needed, for Series 2. Optimal HepB-CpG dosing deserves further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dialysis Clinic Inc, Nashville, TN, USA.
- Tufts Medical Center, Boston, MA, USA.
ORCID-Profile: Jill Frament
Zitieren
APA
Manley, H. J., Aweh, G., Frament, J., Ladik, V., & Lacson, E. K. (2023). A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. Nephrology Dialysis Transplantation, 38(2), 447-454. https://doi.org/10.1093/ndt/gfac039
Vancouver
Manley HJ, Aweh G, Frament J, Ladik V, Lacson EK. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. Nephrology Dialysis Transplantation. 2023;38(2):447-454. doi:10.1093/ndt/gfac039
BibTeX
@article{Manley2023,
author = {Manley, Harold J and Aweh, Gideon and Frament, Jill and Ladik, Vladimir and Lacson, Eduardo K},
title = {A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {2},
pages = {447--454},
doi = {10.1093/ndt/gfac039}
}
EUVIMED